- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06507787
Evaluering av virkningen av EDIT-B®-blodprøven på helsetilstanden til pasienter som presenterer en alvorlig depressiv episode. Klinisk nytte og medisinsk-økonomiske aspekter (SEM EDIT-B)
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.
Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.
The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.
Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.
In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Benjamin Dubuc
- E-post: benjamin.dubuc@alcediag-alcen.com
Studer Kontakt Backup
- Navn: Mary Menhem, PharmD, MSc
- Telefonnummer: +33788970700
- E-post: mary.menhem@alcediag-alcen.com
Studiesteder
-
-
-
Erstein, Frankrike
- Har ikke rekruttert ennå
- CH Erstein
-
Ta kontakt med:
- Geraldine Pfleger, Dr
- Telefonnummer: +33 3 90 64 21 46
- E-post: geraldine.pfleger@ch-erstein.fr
-
Hovedetterforsker:
- Geraldine Pfleger, Dr
-
Issy-les-Moulineaux, Frankrike
- Har ikke rekruttert ennå
- AP-HP Corentin Celton
-
Ta kontakt med:
- Nicolas Hoertel, Pr
- Telefonnummer: +33 1 58 00 44 21
- E-post: nicolas.hoertel@aphp.fr
-
Hovedetterforsker:
- Nicolas Hoertel, Pr
-
La Roche-sur-Foron, Frankrike
- Har ikke rekruttert ennå
- Etablissement Public de Santé Mentale (EPSM) 74
-
Ta kontakt med:
- Rocco De Filippis, Pr
- Telefonnummer: +33 749121443
- E-post: defilippis-r@ch-epsm74.fr
-
Hovedetterforsker:
- Rocco De Filippis, Pr
-
Lyon, Frankrike
- Rekruttering
- Clinique Villa des Roses
-
Ta kontakt med:
- Pascal Frilloux, Dr
- Telefonnummer: +33 4 78 15 00 00
- E-post: pascal.frilloux-ext@inicea.fr
-
Hovedetterforsker:
- Pascal Frilloux, Dr
-
Montrond-les-Bains, Frankrike
- Rekruttering
- Clinique Le Clos Montaigne
-
Ta kontakt med:
- Christophe Aimo, Dr
- Telefonnummer: +33 4 77 36 01 00
- E-post: christophe.aimo@inicea.fr
-
Hovedetterforsker:
- Christophe Aimo, Dr
-
Paris, Frankrike
- Rekruttering
- GHU Paris Psychiatrie et Neurosciences
-
Ta kontakt med:
- Juan Zambrano
- Telefonnummer: +33145658153
- E-post: juan.zambrano@ghu-paris.fr
-
Hovedetterforsker:
- Chantal Henry, Pr
-
Ville-d'Avray, Frankrike
- Har ikke rekruttert ennå
- Clinique Médicale de Ville d'Avray
-
Ta kontakt med:
- Jérôme Dischamps
- Telefonnummer: +33147094314
- E-post: jdischamps@wanadoo.fr
-
Hovedetterforsker:
- Jérôme Dischamps
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
-
Age between 18 and 65 years, gender indifferent
-
Benefitting from health insurance coverage
-
Having signed an informed consent and agreed to follow the study protocol to completion
-
Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:
- More than 3 episodes of MDE in personal medical history
- Psychotic symptoms
- Family history of bipolar disorder
- Onset of the first MDE before the age of 25
- Atypical symptoms or mixed features during depressive episodes
- Addiction
- Personal history of suicide attempts
- Resistance to antidepressants
- Postpartum depression within 6 months of birth
Exclusion Criteria:
- Depression in the context of schizophrenia or autism spectrum disorder
- Patient with a well-established diagnosis of bipolar disorder
- Patients who is already receiving a mood stabilizer
- Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
- Neurodegenerative diseases
- Pregnant women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: With EDIT-B test result
The investigator will have the EDIT-B® test result to guide the treatment strategy. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
|
Placebo komparator: Without EDIT-B test result
The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
Tidsramme: 4 months (from inclusion visit to 15-16 weeks visit)
|
Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint. |
4 months (from inclusion visit to 15-16 weeks visit)
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SEM EDIT-B
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .